A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Drotrecogin alfa (Primary)
Indications Embolism and thrombosis; Septic shock; Systemic inflammatory response syndrome
Focus Therapeutic Use
Acronyms PROWESS-SHOCK
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

14 Oct 2021 This trial has been completed in France (End Date: 26 Feb 2012), according to European Clinical Trials Database record.
09 Mar 2012 Planned number of patients changed from 1500 to 1696 as reported by ClinicalTrials.gov.
25 Oct 2011 Status changed from recruiting to discontinued, according to an Eli Lilly media release. The PROWESS-SHOCK trial was discontinued as it failed to meet its primary endpoint. In addition, the drug is being withdrawn from all markets.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com